52
India, facing a rising obesity crisis, has become a focal point for pharmaceutical companies marketing weight-loss drugs. Major obesity medications are set to launch in the country between 2025 and 2026.
These drugs are part of a class called glucagon-like peptide receptor agonists (GLP-1RAs). They work by mimicking a natural hormone that regulates blood sugar and appetite. The drugs help the brain signal feelings of fullness and slow stomach emptying, contributing to weight loss.
Top global pharmaceutical companies, such as Eli Lilly from the US and Denmark’s Novo Nordisk, are preparing to launch their products in India.
